Annual Accounts Receivable
$5.67 B
+$338.60 M+6.35%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual accounts receivable is currently $5.67 billion, with the most recent change of +$338.60 million (+6.35%) on 31 December 2023. During the last 3 years, it has fallen by -$369.20 million (-6.12%). REGN annual accounts receivable is now -6.12% below its all-time high of $6.04 billion, reached on 31 December 2021.REGN Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$6.11 B
+$390.00 M+6.82%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly accounts receivable is currently $6.11 billion, with the most recent change of +$390.00 million (+6.82%) on 30 September 2024. Over the past year, it has increased by +$439.80 million (+7.76%). REGN quarterly accounts receivable is now -12.74% below its all-time high of $7.00 billion, reached on 30 June 2021.REGN Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | +7.8% |
| 3 y3 years | -6.1% | +1.2% |
| 5 y5 years | +140.1% | +158.7% |
REGN Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -6.1% | +6.3% | at high | +26.2% |
| 5 y | 5 years | -6.1% | +140.1% | -12.7% | +158.7% |
| alltime | all time | -6.1% | >+9999.0% | -12.7% | >+9999.0% |
Regeneron Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $6.11 B(+6.8%) |
| June 2024 | - | $5.72 B(+9.5%) |
| Mar 2024 | - | $5.22 B(-7.9%) |
| Dec 2023 | $5.67 B(+6.4%) | $5.67 B(+1.5%) |
| Sept 2023 | - | $5.58 B(+9.0%) |
| June 2023 | - | $5.12 B(+0.1%) |
| Mar 2023 | - | $5.12 B(-3.9%) |
| Dec 2022 | $5.33 B(-11.7%) | $5.33 B(-4.0%) |
| Sept 2022 | - | $5.55 B(+7.5%) |
| June 2022 | - | $5.16 B(+6.7%) |
| Mar 2022 | - | $4.84 B(-19.8%) |
| Dec 2021 | $6.04 B(+46.7%) | $6.04 B(+10.7%) |
| Sept 2021 | - | $5.45 B(-22.1%) |
| June 2021 | - | $7.00 B(+67.7%) |
| Mar 2021 | - | $4.17 B(+1.4%) |
| Dec 2020 | $4.11 B(+74.3%) | $4.11 B(+15.8%) |
| Sept 2020 | - | $3.55 B(+49.3%) |
| June 2020 | - | $2.38 B(-6.0%) |
| Mar 2020 | - | $2.53 B(+7.2%) |
| Dec 2019 | $2.36 B(+5.2%) | $2.36 B(-11.3%) |
| Sept 2019 | - | $2.66 B(+8.3%) |
| June 2019 | - | $2.46 B(+6.5%) |
| Mar 2019 | - | $2.31 B(+2.8%) |
| Dec 2018 | $2.24 B(+13.6%) | $2.24 B(+1.8%) |
| Sept 2018 | - | $2.20 B(+8.0%) |
| June 2018 | - | $2.04 B(+4.9%) |
| Mar 2018 | - | $1.94 B(-1.5%) |
| Dec 2017 | $1.97 B(+22.5%) | $1.97 B(+0.1%) |
| Sept 2017 | - | $1.97 B(+6.9%) |
| June 2017 | - | $1.84 B(+5.4%) |
| Mar 2017 | - | $1.75 B(+8.6%) |
| Dec 2016 | $1.61 B(+9.8%) | $1.61 B(-2.0%) |
| Sept 2016 | - | $1.64 B(-6.2%) |
| June 2016 | - | $1.75 B(-6.1%) |
| Mar 2016 | - | $1.87 B(+27.1%) |
| Dec 2015 | $1.47 B(+50.3%) | $1.47 B(+2.0%) |
| Sept 2015 | - | $1.44 B(+3.2%) |
| June 2015 | - | $1.40 B(+4.2%) |
| Mar 2015 | - | $1.34 B(+37.1%) |
| Dec 2014 | $976.37 M(+2.2%) | $976.37 M(+5.3%) |
| Sept 2014 | - | $927.25 M(+3.7%) |
| June 2014 | - | $893.92 M(-14.7%) |
| Mar 2014 | - | $1.05 B(+9.7%) |
| Dec 2013 | $954.97 M(+37.8%) | $954.97 M(-3.8%) |
| Sept 2013 | - | $992.82 M(+13.3%) |
| June 2013 | - | $876.02 M(+9.1%) |
| Mar 2013 | - | $802.64 M(+15.8%) |
| Dec 2012 | $693.12 M | $693.12 M(+36.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $506.68 M(+44.9%) |
| June 2012 | - | $349.64 M(+119.3%) |
| Mar 2012 | - | $159.46 M(+54.8%) |
| Dec 2011 | $103.03 M(+25.8%) | $103.03 M(+31.3%) |
| Sept 2011 | - | $78.45 M(-7.2%) |
| June 2011 | - | $84.56 M(-4.1%) |
| Mar 2011 | - | $88.16 M(+7.6%) |
| Dec 2010 | $81.92 M(+24.9%) | $81.92 M(-0.4%) |
| Sept 2010 | - | $82.29 M(-13.6%) |
| June 2010 | - | $95.20 M(+32.5%) |
| Mar 2010 | - | $71.86 M(+9.6%) |
| Dec 2009 | $65.57 M(+86.2%) | $65.57 M(-3.2%) |
| Sept 2009 | - | $67.77 M(+12.9%) |
| June 2009 | - | $60.05 M(+24.6%) |
| Mar 2009 | - | $48.21 M(+36.9%) |
| Dec 2008 | $35.21 M(+92.2%) | $35.21 M(-16.6%) |
| Sept 2008 | - | $42.21 M(+28.5%) |
| June 2008 | - | $32.84 M(-0.4%) |
| Mar 2008 | - | $32.96 M(+79.9%) |
| Dec 2007 | $18.32 M(+144.5%) | $18.32 M(+67.0%) |
| Sept 2007 | - | $10.97 M(-46.4%) |
| June 2007 | - | $20.48 M(-39.1%) |
| Mar 2007 | - | $33.63 M(+348.8%) |
| Dec 2006 | $7.49 M(-79.5%) | $7.49 M(-5.6%) |
| Sept 2006 | - | $7.94 M(-34.6%) |
| June 2006 | - | $12.14 M(+10.3%) |
| Mar 2006 | - | $11.01 M(-69.9%) |
| Dec 2005 | $36.52 M(-15.3%) | $36.52 M(+246.6%) |
| Sept 2005 | - | $10.54 M(-37.4%) |
| June 2005 | - | $16.83 M(+62.3%) |
| Mar 2005 | - | $10.37 M(-75.9%) |
| Dec 2004 | $43.10 M(+177.6%) | $43.10 M(+73.3%) |
| Sept 2004 | - | $24.87 M(-2.1%) |
| June 2004 | - | $25.40 M(-57.6%) |
| Mar 2004 | - | $59.88 M(+285.6%) |
| Dec 2003 | $15.53 M(+286.6%) | $15.53 M(+68.8%) |
| Sept 2003 | - | $9.20 M(+16.8%) |
| June 2003 | - | $7.87 M(+8.7%) |
| Mar 2003 | - | $7.24 M(+80.2%) |
| Dec 2002 | $4.02 M(+35.0%) | $4.02 M(-11.1%) |
| Sept 2002 | - | $4.52 M(+51.4%) |
| June 2002 | - | $2.99 M(+9.0%) |
| Mar 2002 | - | $2.74 M(-7.9%) |
| Dec 2001 | $2.98 M(-78.5%) | $2.98 M(-16.1%) |
| Sept 2001 | - | $3.55 M(-19.0%) |
| June 2001 | - | $4.38 M(-49.1%) |
| Mar 2001 | - | $8.61 M(-37.8%) |
| Dec 2000 | $13.84 M | $13.84 M |
FAQ
- What is Regeneron Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Regeneron Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of REGN is $5.67 B
What is the all time high annual accounts receivable for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual accounts receivable is $6.04 B
What is Regeneron Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of REGN is $6.11 B
What is the all time high quarterly accounts receivable for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly accounts receivable is $7.00 B
What is Regeneron Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, REGN quarterly accounts receivable has changed by +$439.80 M (+7.76%)